SEC Company Response from Outlook Therapeutics, (OTLK) — May 5, 2016

Outlook Therapeutics, Inc.
Date: May 5, 2016 · CIK: 0001649989 · Accession: 0001571049-16-014897

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-209011

Date

May 5, 2016

Author

Not clearly detected

Form

CORRESP

Company

Outlook Therapeutics, Inc.

Letter

Re: Oncobiologics, Inc.

May 5, 2016

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Ms. Suzanne Hayes

Registration Statement on Form S-1

Filed April 27, 2016

File No. 333-209011

Withdrawal of Acceleration Request

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence via EDGAR on May 4, 2016, in which we requested the acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-209011) for Thursday, May 5, 2016, at 4:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such registration statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.

Very truly yours,
Oncobiologics, Inc.

Show Raw Text

CORRESP
1
filename1.htm

May 5, 2016

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: 	 Ms. Suzanne Hayes

Re: Oncobiologics, Inc.

Registration Statement on Form S-1

Filed April 27, 2016

File No. 333-209011

  Withdrawal of Acceleration Request

Ladies and Gentlemen:

Reference is made
to our letter, filed as correspondence via EDGAR on May 4, 2016, in which we requested the acceleration of the effective date of
the above-referenced Registration Statement on Form S-1 (File No. 333-209011) for Thursday, May 5, 2016, at 4:00 p.m. Eastern Time,
in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such registration statement
be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.

    Very truly yours,

    Oncobiologics, Inc.

    By:   /s/ Pankaj Mohan

    Pankaj Mohan, Ph.D.

    Chairman, President and Chief Executive Officer

 cc: Lawrence A. Kenyon, Oncobiologics, Inc.

  Yvan-Claude Pierre, Cooley LLP

  Daniel I. Goldberg, Cooley LLP

  Marianne Sarrazin, Cooley LLP

  Edwin O’Connor, Goodwin Procter LLP

  Seo Salimi, Goodwin Procter LLP

    7 Clarke Drive, Cranbury, NJ 08512
      (609) 619-3990

SecProbe.io